Literature DB >> 11131456

Splanchnic metabolism of fuel substrates in acute liver failure.

J O Clemmesen1, C E Høy, J Kondrup, P Ott.   

Abstract

BACKGROUND/AIMS: This study aimed to characterize the exchange of fuel substrates in the splanchnic circulation in acute liver failure.
METHODS: Liver vein catheterization was used in 22 patients with acute liver failure after development of hepatic encephalopathy grade III-IV Healthy controls, patients with cirrhosis and patients with acute on chronic liver disease were also studied.
RESULTS: In acute liver failure there was splanchnic removal of glucose (0.21+/-0.44 mmol/min), release of lactate (0.34+/-0.37 mmol/min), pyruvate (0.08+/-0.06 mmol/min) and ketone bodies (0.04+/-0.02 mmol/min), while extraction of amino acids and free fatty acids was insignificant. In the acute liver failure group, a normal hepatic venous oxygen saturation (0.69+/-0.12) and normal pyruvate/lactate ratio suggested absence of hypoxia even though the acetoacetate/beta-hydroxybutyrate ratio was decreased. Only in the acute liver failure group did the measured splanchnic oxygen content difference exceed what could be accounted for even by hypothesizing complete oxidation of all extracted blood-borne fuel substrates; oxidation of endogenous substrates may be quantitatively important in this condition.
CONCLUSION: Acute liver failure was associated with a state of accelerated glycolysis in the splanchnic region, leading to release of lactate in the absence of splanchnic hypoxia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11131456     DOI: 10.1016/s0168-8278(00)80126-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

1.  Prognostic Utility of Initial Lactate in Patients With Acute Drug Overdose: A Validation Cohort.

Authors:  Randy Cheung; Robert S Hoffman; David Vlahov; Alex F Manini
Journal:  Ann Emerg Med       Date:  2018-04-06       Impact factor: 5.721

2.  ESPEN guideline on clinical nutrition in liver disease.

Authors:  Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2019-01-16       Impact factor: 7.324

Review 3.  Cerebral effects of ammonia in liver disease: current hypotheses.

Authors:  Peter Ott; Hendrik Vilstrup
Journal:  Metab Brain Dis       Date:  2014-02-04       Impact factor: 3.584

Review 4.  Etiology and therapeutic approach to elevated lactate levels.

Authors:  Lars W Andersen; Julie Mackenhauer; Jonathan C Roberts; Katherine M Berg; Michael N Cocchi; Michael W Donnino
Journal:  Mayo Clin Proc       Date:  2013-10       Impact factor: 7.616

5.  Hyperlactatemia in patients with non-acetaminophen-related acute liver failure.

Authors:  Pilar Taurá; Graciela Martinez-Palli; Julia Martinez-Ocon; Joan Beltran; Gerard Sanchez-Etayo; Jaume Balust; Teresa Anglada; Antoni Mas; Juan-Carlos Garcia-Valdecasas
Journal:  World J Gastroenterol       Date:  2006-03-28       Impact factor: 5.742

Review 6.  [Acute liver failure].

Authors:  K Rifai; M J Bahr
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

Review 7.  Elevated cerebral lactate: Implications in the pathogenesis of hepatic encephalopathy.

Authors:  Cristina R Bosoi; Christopher F Rose
Journal:  Metab Brain Dis       Date:  2014-06-11       Impact factor: 3.584

8.  The association of early combined lactate and glucose levels with subsequent renal and liver dysfunction and hospital mortality in critically ill patients.

Authors:  Pedro Freire Jorge; Nienke Wieringa; Eva de Felice; Iwan C C van der Horst; Annemieke Oude Lansink; Maarten W Nijsten
Journal:  Crit Care       Date:  2017-08-21       Impact factor: 9.097

Review 9.  Hepatology - Guidelines on Parenteral Nutrition, Chapter 16.

Authors:  M Plauth; T Schuetz
Journal:  Ger Med Sci       Date:  2009-11-18

Review 10.  Quantitative Assessment of Blood Lactate in Shock: Measure of Hypoxia or Beneficial Energy Source.

Authors:  David G Levitt; Joseph E Levitt; Michael D Levitt
Journal:  Biomed Res Int       Date:  2020-10-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.